1,721,155 research outputs found
Grey zones in the practice of permanent cardiac pacing: The case of preventive pacing for improving rhythm control in atrial fibrillation
No full textCHA2DS2-VA instead of CHA2DS2-VASc for stroke risk stratification in patients with atrial fibrillation: not just a matter of sex
Full text linkFrom meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach
No full textPermanent Atrial Fibrillation as the Terminal Stage of a Chronic Disease: Palliative Care Needs to be Considered in Selected Patients with Markedly Impaired Quality of Life
No full textFlecainide and atrial fibrillation cardioversion: what solutions at present and in the near future?
Full text link
Oral anticoagulants in patients with atrial fibrillation and end-stage renal disease: Walking the tightrope between thromboembolic and bleeding risk
No full textImplantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the ‘real world’?
No full textProgression of Atrial Fibrillation after Cryoablation
No full textTo the Editor: Andrade et al. (Jan. 12 issue)(1) found that an initial strategy of catheter cryoballoon ablation in patients with paroxysmal atrial fibrillation was associated with a lower incidence of persistent atrial fibrillation, and a lower burden of arrhythmia than therapy with antiarrhythmic drugs during 3 years of follow-up. The article extends the initial findings of the Early Aggressive Invasive Intervention for Atrial Fibrillation (EARLY-AF) trial.(2) Given the number of participants (303 patients) and the relatively short follow-up, it would have been difficult to detect mortality benefits of cryoballoon ablation. Both the EARLY-AF and the STOP AF First(3) trials . .
Cardiac resynchronization therapy: Need to synchronize patients and device longevities with comorbidities
No full text- …
